New Cent. Aim Vct 2
The Board is pleased to announce that in accordance with the terms of the Offer
dated 12th March 2007, [the Offer] 2,115,000 shares of 10p each were allotted on
the 5th April 2007 at 100p per share.
Within this figure the following Directors and connected parties have been
alloted shares
-0-
*T
Number %of Issue
Peter Riley 3,000 0.05
Mrs Susan Lucille Riley
[wife of Peter Riley] 30,000 0.52
Michael David Barnard 250,000 4.35
John Brice 50,000 0.87
Geoffrey Charles Gamble 176,000 3.06
*T
Application has been made for the admission of the 2,115,000 shares to the
Official List of the UK Listing Authority and to trading on London Stock
Exchange's plc's market for listed securities.
The Offer has now closed
The number of ordinary shares in issue as at 5th April 2007, together with
voting rights under Provision 6, following the above allotment, stands at
5,745,530..
The foregoing figure may be used by shareholders as the denominator for the
calculation by which they will determine if they are required to notify their
interest in, or a change of their interest in, the Company under FSA's
Disclosure and Transparency Rules.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.